JP2005502643A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502643A5
JP2005502643A5 JP2003518549A JP2003518549A JP2005502643A5 JP 2005502643 A5 JP2005502643 A5 JP 2005502643A5 JP 2003518549 A JP2003518549 A JP 2003518549A JP 2003518549 A JP2003518549 A JP 2003518549A JP 2005502643 A5 JP2005502643 A5 JP 2005502643A5
Authority
JP
Japan
Prior art keywords
compound
leukemia
tyrosine kinase
kinase activity
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003518549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502643A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/008941 external-priority patent/WO2003013540A1/en
Publication of JP2005502643A publication Critical patent/JP2005502643A/ja
Publication of JP2005502643A5 publication Critical patent/JP2005502643A5/ja
Withdrawn legal-status Critical Current

Links

JP2003518549A 2001-08-10 2002-08-09 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用 Withdrawn JP2005502643A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31169001P 2001-08-10 2001-08-10
PCT/EP2002/008941 WO2003013540A1 (en) 2001-08-10 2002-08-09 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Publications (2)

Publication Number Publication Date
JP2005502643A JP2005502643A (ja) 2005-01-27
JP2005502643A5 true JP2005502643A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=23208019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518549A Withdrawn JP2005502643A (ja) 2001-08-10 2002-08-09 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用

Country Status (6)

Country Link
US (5) US20040248906A1 (cg-RX-API-DMAC7.html)
EP (2) EP1418917A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005502643A (cg-RX-API-DMAC7.html)
CN (1) CN1523991A (cg-RX-API-DMAC7.html)
CA (2) CA2450777C (cg-RX-API-DMAC7.html)
WO (1) WO2003013540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2003047523A2 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US20050009891A1 (en) 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
CN1918158B (zh) * 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CA2584493A1 (en) 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
CN101106983A (zh) * 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
US20090306094A1 (en) * 2006-03-17 2009-12-10 Bristol-Myers Squibb Company Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides
AU2007235976A1 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP2117544A4 (en) * 2006-12-19 2010-03-03 Univ Texas BIOMARKER FOR IDENTIFYING REACTIVATION FROM STAT3 TO SRC INHIBITION
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
CN103319488A (zh) * 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
IN2012CH01573A (cg-RX-API-DMAC7.html) * 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
HK1208460A1 (en) * 2012-05-31 2016-03-04 Gb005, Inc. Protein kinase inhibitors
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
US10144828B2 (en) 2012-11-21 2018-12-04 Stratasys, Inc. Semi-crystalline build materials
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3174539A4 (en) 2014-08-01 2017-12-13 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
CA3083231A1 (en) 2017-11-29 2019-06-06 Adaptive Phage Therapeutics, Inc. Methods of vaccination using icosahedral phage
HRP20250480T1 (hr) 2018-09-10 2025-06-20 Mirati Therapeutics, Inc Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
WO2021252450A1 (en) 2020-06-08 2021-12-16 Adaptive Phage Therapeutics, Inc. Phage display vaccine for covid-19 using a novel peptide sequence
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JP4145955B2 (ja) 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用
GB9516842D0 (en) 1995-08-17 1995-10-18 Ciba Geigy Ag Various acylated oligopeptides
GB9517060D0 (en) 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
US7091346B1 (en) * 1995-11-01 2006-08-15 Novartis Ag Purine derivatives and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20050215795A1 (en) 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2005502643A5 (cg-RX-API-DMAC7.html)
JP2009532438A5 (cg-RX-API-DMAC7.html)
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
KR102293847B1 (ko) 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도
JP2004531549A5 (cg-RX-API-DMAC7.html)
JP2024133474A5 (cg-RX-API-DMAC7.html)
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2003528917A5 (cg-RX-API-DMAC7.html)
US20110166092A1 (en) Dosing methods for treating disease
JP2019517587A5 (cg-RX-API-DMAC7.html)
JP2006514092A5 (cg-RX-API-DMAC7.html)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
RU2002115406A (ru) Соединение, обладающее свойствами высвобождения гормона роста
JP2020529995A (ja) 行動の変化の治療方法
CN1511036A (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
BG108339A (bg) Лечение на деменция и дегенеративни разстройства с междинни дози lhrh-антагонисти
JP2021522246A (ja) 癌治療のための併用
TR201806682T4 (tr) Farmasötik kombinasyonlar.
TWI841027B (zh) 手部溼疹之治療
JP2006505582A5 (cg-RX-API-DMAC7.html)
JP2009511450A5 (cg-RX-API-DMAC7.html)
RU2006125741A (ru) Комбинация (а) n-{5-[4-(4-метилпиперазинометил)бензоиламило]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамина и (б) по меньшей мере одного ингибитора гипузинации и ее применение
JP2007514699A5 (cg-RX-API-DMAC7.html)
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia